Daily Stock Analysis, ADAP, Adaptimmune Therapeutics PLC, priceseries

Adaptimmune Therapeutics PLC. Daily Stock Analysis
Stock Information
Open
7.92
Close
8.11
High
8.16
Low
7.79
Previous Close
7.88
Daily Price Gain
0.22
YTD High
9.29
YTD High Date
Sep 11, 2017
YTD Low
3.88
YTD Low Date
Feb 23, 2017
YTD Price Change
3.99
YTD Gain
96.84%
52 Week High
9.29
52 Week High Date
Sep 11, 2017
52 Week Low
3.76
52 Week Low Date
Dec 15, 2016
52 Week Price Change
3.18
52 Week Gain
64.50%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 19. 2015
8.20
Nov 9. 2015
11.20
15 Trading Days
36.60%
Link
LONG
Dec 18. 2015
9.49
Jan 7. 2016
11.05
12 Trading Days
16.45%
Link
LONG
Mar 31. 2016
8.13
Apr 19. 2016
9.28
13 Trading Days
14.10%
Link
LONG
May 18. 2016
9.32
May 27. 2016
9.88
7 Trading Days
6.04%
Link
LONG
Nov 8. 2016
4.49
Nov 23. 2016
4.75
11 Trading Days
5.78%
Link
LONG
Mar 27. 2017
4.57
Apr 18. 2017
5.68
15 Trading Days
24.35%
Link
LONG
Jul 12. 2017
5.09
Jul 26. 2017
5.41
10 Trading Days
6.34%
Link
LONG
Aug 28. 2017
6.00
Sep 19. 2017
8.00
15 Trading Days
33.25%
Link
Company Information
Stock Symbol
ADAP
Exchange
NasdaqGS
Company URL
http://http://www.adaptimmune.com
Company Phone
44 1235 430000
CEO
James Julian Noble
Headquarters
-
Business Address
101 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RY
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001621227
About

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform.

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead program includes NY-ESO cancer antigen, which is in Phase 1/2 clinical trials for the treatment of patients with solid tumors, as well as hematological cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune Therapeutics plc is also developing MAGE A-10 TCR that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and other solid tumors; and Alpha Fetoprotein TCR therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.